RESEARCH IN ENGLAND

Explore clinical trials with England locations

Search 2,970 registered studies with identifiable England locations in our dated ClinicalTrials.gov snapshot. Explore the study and local recruitment details before contacting the research team.

Condition, study or locationRecorded care areaStatus at an England locationClear filters

208 matching studies · ordered by study identifier.

The area filter uses exact source postcodes. Locations without a matched postcode remain in the England-wide results.

NCT05727904 · Interventional

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

Metastatic Melanoma · Unresectable Melanoma · Melanoma

Study overall: Recruiting · source record updated 26 June 2026.

5 England locations · 5 explicitly recorded as recruiting.

NCT05745714 · Interventional

HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

Acute Lymphoblastic Leukemia, in Relapse · Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent · Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent · Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory · Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

Study overall: Recruiting · source record updated 16 September 2025.

4 England locations · 0 explicitly recorded as recruiting.

NCT05751044 · Interventional

HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

Acute Lymphoblastic Leukemia · Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent · Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent · Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory · Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

Study overall: Recruiting · source record updated 16 September 2025.

4 England locations · 0 explicitly recorded as recruiting.

NCT05768178 · Interventional

DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

Haematological Malignancy · Melanoma · Thyroid Cancer, Papillary · Ovarian Neoplasms · Colorectal Neoplasms · Laryngeal Neoplasms · Carcinoma, Non-Small-Cell Lung · Glioma · Multiple Myeloma · Erdheim-Chester Disease · Thyroid Carcinoma, Anaplastic · Solid Tumour

Study overall: Recruiting · source record updated 24 November 2025.

12 England locations · 12 explicitly recorded as recruiting.

NCT05770037 · Interventional

DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers

Haematological Malignancy · Malignant Neoplasm · Lymphoproliferative Disorders · Neoplasms by Histologic Type · Neoplasms by Site · Cancer · Anaplastic Large Cell Lymphoma · Lymphoma · Renal Cell Carcinoma · Neuroblastoma · Solid Tumour

Study overall: Recruiting · source record updated 24 November 2025.

21 England locations · 19 explicitly recorded as recruiting.

NCT05770102 · Interventional

DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition

Malignancy · Malignant Neoplasm · Lymphoproliferative Disorders · Neoplasms by Histologic Type · Neoplasms by Site · Cancer · Colorectal Neoplasms · Endometrial Neoplasms · Melanoma · Solid Tumours

Study overall: Recruiting · source record updated 24 November 2025.

21 England locations · 19 explicitly recorded as recruiting.

NCT05770544 · Interventional

DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.

Haematological Malignancy · Malignancy · Malignant Neoplasm · Lymphoproliferative Disorders · Neoplasms by Histologic Type · Neoplasms by Site · Cancer · Brain Neoplasms · Melanoma · Glioma · Solid Tumour

Study overall: Recruiting · source record updated 24 November 2025.

21 England locations · 19 explicitly recorded as recruiting.

NCT05786716 · Interventional

DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations

Haematological Malignancy · Colorectal Neoplasms · Urinary Bladder Neoplasm · Gallbladder Neoplasms · Salivary Gland Neoplasm · Lung Neoplasm · Pancreatic Neoplasm · Ovarian Neoplasms · Prostatic Neoplasm · Skin Neoplasm · Solid Tumour

Study overall: Recruiting · source record updated 2 December 2025.

21 England locations · 19 explicitly recorded as recruiting.

NCT05789758 · Observational

A Study to Learn How Nusinersen (Spinraza) Affects Participants With Spinal Muscular Atrophy (SMA) Who Took it Before or During Pregnancy And About The Health of Their Babies

Muscular Atrophy, Spinal

Study overall: Recruiting · source record updated 9 March 2026.

10 England locations · 10 explicitly recorded as recruiting.

NCT05836324 · Interventional

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

Solid Tumors · Advanced Solid Tumors · Metastatic Solid Tumors

Study overall: Recruiting · source record updated 23 July 2026.

5 England locations · 5 explicitly recorded as recruiting.

NCT05882058 · Interventional

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

Small Cell Lung Carcinoma · Neuroendocrine Neoplasms · Extra-pulmonary Neuroendocrine Carcinoma

Study overall: Recruiting · source record updated 23 July 2026.

4 England locations · 4 explicitly recorded as recruiting.

NCT05933057 · Interventional

Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

Study overall: Recruiting · source record updated 24 July 2026.

2 England locations · 0 explicitly recorded as recruiting.

NCT05935215 · Interventional

Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

Atypical Hemolytic Uremic Syndrome

Study overall: Recruiting · source record updated 29 April 2026.

2 England locations · 2 explicitly recorded as recruiting.

NCT05958030 · Interventional

GyroGlove Use in Essential Tremor Patients

Essential Tremor

Study overall: Not yet recruiting · source record updated 14 March 2025.

4 England locations · 0 explicitly recorded as recruiting.

NCT06051617 · Interventional

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

Primary Biliary Cholangitis

Study overall: Recruiting · source record updated 11 August 2026.

10 England locations · 10 explicitly recorded as recruiting.

NCT06215716 · Interventional

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

NASH With Fibrosis · MASH With Fibrosis

Study overall: Recruiting · source record updated 7 August 2026.

9 England locations · 8 explicitly recorded as recruiting.

NCT06217822 · Interventional

First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

Advanced Metastatic Castration-resistant Prostate Cancer · Prostate Specific Membrane Antigen (PSMA) Expression

Study overall: Recruiting · source record updated 7 July 2026.

3 England locations · 2 explicitly recorded as recruiting.

NCT06312137 · Interventional

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Non Small Cell Lung Cancer

Study overall: Recruiting · source record updated 21 August 2026.

5 England locations · 5 explicitly recorded as recruiting.

NCT06319820 · Interventional

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

Non-Muscle Invasive Bladder Neoplasms

Study overall: Recruiting · source record updated 28 August 2026.

7 England locations · 7 explicitly recorded as recruiting.

NCT06324357 · Interventional

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Metastatic Breast Cancer · Metastatic Gastric Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma · Esophageal Adenocarcinoma · Colorectal Cancer

Study overall: Recruiting · source record updated 6 August 2026.

9 England locations · 7 explicitly recorded as recruiting.

More ways to explore research

This is a selected international registry feed, not every study taking place in England. NIHR also lists participation opportunities, including studies that may not appear in this selection.

NIHR Be Part of Research Search the original register

Source: ClinicalTrials.gov, a United States Government database. Contains OS data © Crown copyright and database right 2026. Contains National Statistics data © Crown copyright and database right 2024; ONS country boundaries (December 2024).

Source processed: 2026-09-10 09:00:04 UTC. Retrieved: 10 September 2026. ClinicalTrials.gov terms.

How we selected and connected these records

Selected registered studies with an overall status of Recruiting or Not yet recruiting and at least one England location established by postcode, recorded nation, or source coordinates within the ONS December 2024 boundary. Retained structured fields; omitted descriptions, eligibility text, contacts and non-England locations. Deduplicated identical locations. Linked local care areas only by exact postcode geography. Location points are used for nation filtering, not directions or facility matching.